EP2880024A1 - Griseofulvinderivate - Google Patents

Griseofulvinderivate

Info

Publication number
EP2880024A1
EP2880024A1 EP13744551.6A EP13744551A EP2880024A1 EP 2880024 A1 EP2880024 A1 EP 2880024A1 EP 13744551 A EP13744551 A EP 13744551A EP 2880024 A1 EP2880024 A1 EP 2880024A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
group
aryl
heterocycle
rrrr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13744551.6A
Other languages
English (en)
French (fr)
Inventor
Frédéric MARION
Frédéric LIEBY-MULLER
Serge Grisoni
Emmanuel FOURNIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of EP2880024A1 publication Critical patent/EP2880024A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Definitions

  • the present invention relates to griseofulvin derivatives and their use for the treatment of cancerous and pre-cancerous hyperproliferative pathologies.
  • Griseofulvin 1 is a natural molecule isolated from filamentous fungus cultures Penicilium griseofulvum [J. Chem. Soc. 1958, 360-365]. It is used in the treatment of fungal diseases of the skin in humans and is also used in veterinary medicine. It is administered primarily orally at doses of 0.5 to 1.0 grams per day in humans.
  • griseofulvin derivatives substituted at 2 'with oxygen or sulfur groups [J. Med. Chem. 2009, 3342-3347] have been synthesized. However, none of these products has demonstrated the potential to be used as a drug in the treatment of cancerous and pre-cancerous hyperproliferative diseases.
  • the inventors have thus surprisingly discovered that the addition of a particular 2 'and / or 3' group makes it possible to obtain more potent cytotoxic derivatives than griseofulvin and that its analogs previously described have remarkable activity on cancerous lines. particularly resistant to known cytotoxic agents.
  • the present invention thus relates to a compound of general formula (I) below:
  • rrrr represents a single or double bond
  • Z represents a group -S (O) R 7 or -S (O) 2 R 7
  • Z represents a hydrogen atom or a group R 9 and X represents a group CH-Rio when rrrr represents a single bond or C-Rio when rrrr represents a double bond,
  • ⁇ Ri to R 5 representing, independently of each other, a hydrogen atom or a (Ci-C 6) alkyl, aryl, (Ci-C 6) alkyl-aryl, aryl- (Ci-C 6) alkyl or 5- or 6-membered heterocycle,
  • ⁇ R O is a hydrogen atom or a (Ci-Ce) alkyl, aryl, (Cl- C6) alkyl-aryl, aryl- (Ci-C 6) alkyl, C (0) NH 2, C ( S) NH 2 or 5- or 6-membered heterocycle,
  • R 7 is (C 1 -C 6) alkyl, aryl, (C 1 -C 6 ) alkyl-aryl, aryl (C 1 -C 6 ) alkyl or 5- or 6-membered heterocycle,
  • R 9 is a group -R 4, -NHRi, -CH 2 -NHRi 4, -CH 2 -CH 2 -NH-C (O) -Rn, -NH-CH 2 -Rn, -NH-NH-Rn, -NH-C ( 0) -Rn, -NH-C (O) -CH 2 -Rn, -NH-CH 2 -C (O) -Rn, -NH-CH 2 -C (O) -O-Rn, -NH-CH 2 -C (O) -NH-Rn, -NH-S0 2 -Rn, -S (O) -Rn, -SO 2 -Rn, -S (O) -CH 2 -R n , -SO 2 -CH 2 -R n , or -NRi 2 Ri 3
  • ⁇ R 9 is a group -R 4, -NHRi, -CH 2 -NHRi
  • ⁇ Ru represents a hydrogen atom or a (Ci-Ce) alkyl, carbocycle, heterocycle, biaryl, carbocycle- (Ci-C6) alkyl or heterocycle (Ci-C6) alkyl optionally substituted,
  • ⁇ R12 and R13 form, together with the nitrogen atom which carries them, a heterocycle optionally substituted with one -rU group, or -ORn -NHRn,
  • R 4 is (C 1 -C 6) alkyl, carbocycle, heterocycle, biaryl, carbocycle (C 1 -C 6) alkyl or optionally substituted (C 1 -C 6) alkyl heterocycle,
  • R 15 is optionally substituted (C 1 -C 6 ) alkyl, optionally substituted aryl, (C 1 -C 6 ) alkyl aryl, aryl (C 1 -C 6) alkyl, carbocycle, optionally substituted heterocycle, biaryl, carbocycle (C 1 -C 6 ) C6) alkyl or heterocycle (Ci-C 6) alkyl, and
  • Ri6 and Ri 7 together with the nitrogen atom carrying them a heterocycle optionally substituted with a group -Ri 4 , -ORi 4 or -NHRi.
  • part Y of the molecule of formula (I) mentioned above may comprise one or more asymmetric carbon atoms which may each be present in the R or S configuration or in the form of a mixture of the two configurations R and S in all proportions, especially in equimolar proportions.
  • the term "pharmaceutically acceptable” means that which is useful in the preparation of a pharmaceutical composition which is generally safe, non-toxic and neither biologically nor otherwise undesirable and which is acceptable for veterinary as well as pharmaceutical use. human.
  • pharmaceutically acceptable salts of a compound is meant in the present invention salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity of the parent compound.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulphonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaphthoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, dibenzoyl-L-tartaric acid, tartaric acid, p-acid toluenesulphonic acid, trimethylacetic acid, trifluoroacetic acid and the like.
  • organic acids such as acetic acid, benz
  • halogen atom means the fluorine, chlorine, bromine and iodine atoms.
  • (Ci-C 6) alkyl is understood within the meaning of the present invention, a saturated hydrocarbon chain, linear or branched, having 1 to 6 carbon atoms. It may be in particular a methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl or n-hexyl group.
  • (C 1 -C 6 ) alkoxy means a (C 1 -C 6 ) alkyl group as defined above bonded to the remainder of the molecule via an atom. oxygen. It may be in particular a methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, n-pentoxy or n-hexoxy group.
  • aryl means an aromatic hydrocarbon group preferably comprising from 5 to 10 carbon atoms and comprising one or more contiguous rings, preferably 1 or 2 rings, for example a grouping. phenyl or naphthyl. Advantageously, it is phenyl.
  • (Ci-C 6 ) alkyl-aryl means a (C 1 -C 6 ) alkyl group as defined above bonded to the remainder of the molecule by via an aryl group as defined above. It may be in particular a tolyl group.
  • aryl- (Ci-C 6) alkyl is understood within the meaning of the present invention, an aryl group as defined above bound to the rest of the molecule via a (Ci-C 6 ) alkyl as defined above. It may be in particular a benzyl group.
  • biasing is meant, within the meaning of the present invention, an aryl group as defined above linked to the remainder of the molecule through an aryl group as defined above. It may be in particular a biphenyl group.
  • heteroaryl group is meant, in the sense of the present invention, an aryl group as defined above in which one or more carbon atoms have been replaced by one or more heteroatoms, advantageously 1 to 4, preferably 1 to or 2.
  • heteroaryl groups are pyridine, pyrimidine, pyrazine, pyridazine, furan, thiophene, pyrrole, pyrazole, imidazole, thiazole, isothiazole, oxazole, isoxazole, triazole, tetrazole, benzo furan, benzothiophene, indole, benzimidazole, indazole, quinoline, isoquinoline, quinazoline or quinoxaline.
  • heteroatom in particular an atom of sulfur, nitrogen or oxygen.
  • the term "carbocycle” means one or more contiguous rings, preferably 1 or 2 fused, hydrocarbon, saturated, unsaturated or aromatic rings, each ring advantageously having 3 to 8 ring members, preferably 3, 5, 6 or 7 members, and more preferably 5 or 6 members. It may be in particular cycloalkyl, such as cyclopentyl or cyclohexyl.
  • the term "unsaturated" means that the ring comprises one or more double bonds.
  • the term "carbocycle- (C 1 -C 6 ) alkyl” is intended to mean a carbocycle group as defined above bonded to the remainder of the molecule via a (Ci-C) group. 6 ) alkyl as defined above, and preferably via a group -CH 2 -. It may be in particular a cyclopentylmethyl or cyclohexylmethyl group.
  • heterocycle is intended to mean a carbocycle group as defined above in which one or more carbon atoms have have been replaced by one or more heteroatoms, advantageously 1 to 4, preferably 1 or 2.
  • heterocycle comprising a single ring are epoxide rings, aziridine, furan, dihydrofuran, tetrahydrofuran, pyrrole, pyroline, pyrrolidine, thiophene, dihydrothiophene , tetrahydrothiophene, pyrazole, pyrazoline, pyrazolidine, imidazole, imidazoline, imizadolidine, thiazole, dihydrothiazole, tétrahydrothiazole, oxazole, dihydrooxazole, tétrahydrooxazole, triazoles, dihydrotriazoles, tétrahydrotriazoles, pyridine, dihydropyridine, tetrahydr
  • heterocycles comprising two fused rings are the aforementioned 1-ringed heterocycles fused with one phenyl ring, such as indole, benzofuran, benzopyrans including chromene and isochromene, and dihydrobenzopyrans including chroman and quinoline. dihydroquinolines, tetrahydroquinoline, isoquinoline, dihydroisoquinolines and tetrahydroisoquinoline.
  • (C 1 -C 6 ) -cyclo-heterocycle means a heterocycle group as defined above bonded to the remainder of the molecule via a (C 1 -C 4) group. 6 ) alkyl as defined above, and preferably via a group -CH 2 -.
  • cycloalkyl is intended to mean a saturated hydrocarbon monocycle, advantageously comprising 3 to 8 carbon atoms, in particular 5 or 6. This may especially be cyclohexyl.
  • R 1 to R 5 represent, independently of one another, a hydrogen atom or a (C 1 -C 6 ) alkyl, aryl, (C 1 -C 6 ) alkyl-aryl or aryl- (C 1 -C 6 ) alkyl group ,
  • ⁇ R O represents a hydrogen atom or a (Ci-C 6) alkyl, aryl, (Cl- C6) alkyl-aryl, aryl- (Ci-C 6) alkyl, C (0) NH 2 or C (S) NH 2
  • ⁇ R 7 represents a (Ci-Ce) alkyl, aryl, (Ci-C6) alkyl-aryl or aryl- (Cl- C6) alkyl.
  • rrrr will advantageously represent a double bond.
  • Z represents a group -S (O) R 7 or -S (O) 2 R 7
  • R 7 represents a (C 1 -C 6) alkyl, aryl, (C 1 -C 6) alkylaryl or aryl (C 1 -C 6) group;
  • C 6 alkyl, preferably an aryl or (C 1 -C 6 ) alkyl-aryl group.
  • Ru will advantageously represent a hydrogen atom or a (C 1 -C 6 ) alkyl, carbocycle, heterocycle, biaryl, carbocycle- (C 1 -C 6 ) alkyl or optionally substituted (C 1 -C 6 ) alkyl heterocycle; in particular a hydrogen atom or a (C 1 -C 6) alkyl, carbocycle, heterocycle or optionally substituted biaryl group; preferentially a hydrogen atom or a (C 1 -C 6 ) alkyl group such as a CH 3 group; for example a hydrogen atom,
  • the carbocycle being advantageously a cycloalkyl such as cyclohexyl or an aryl such as phenyl or naphthyl,
  • the heterocycle being advantageously pyridine, pyrimidine, pyridazine, pyrazine, furan, thiophene, pyrrole, pyrazole, imidazole, thiazole, oxazole, triazoles, benzo furan, benzothiophene, indole, 1,3-benzodioxolane, piperidine, morpholine or piperazine; more particularly pyridine, furan, thiophene, pyrrole, benzofuran, benzothiophene, indole, 1,3-benzodioxolane or piperidine; and especially pyridine, furan, thiophene, benzofuran, 1,3-benzodioxolane or piperidine, and the biaryl being advantageously biphenyl.
  • Z preferably represents a hydrogen atom.
  • R9 preferably represents a group R14
  • R 14 then preferably representing a hydrogen atom or a (C 1 -C 6 ) alkyl, carbocycle, heterocycle, biaryl, carbocycle- (C 1 -C 6 ) alkyl or optionally substituted (C 1 -C 6 ) alkyl heterocycle; in particular a (C 1 -C 6) alkyl, carbocycle, heterocycle or optionally substituted baryl group; preferentially a (C 1 -C 6 ) alkyl group such as a CH 3 group,
  • the carbocycle being advantageously a cycloalkyl such as cyclohexyl or an aryl such as phenyl or naphthyl,
  • the heterocycle being advantageously pyridine, pyrimidine, pyridazine, pyrazine, furan, thiophene, pyrrole, pyrazole, imidazole, thiazole, oxazole, triazoles, benzo furan, benzothiophene, indole, 1,3-benzodioxolane, piperidine, morpholine or piperazine; more particularly pyridine, furan, thiophene, pyrrole, benzofuran, benzothiophene, indole, 1,3-benzodioxolane or piperidine; and especially pyridine, furan, thiophene, benzofuran, 1,3-benzodioxolane or piperidine, and
  • the biaryl being advantageously biphenyl.
  • the groups R 22 to R 25 representing, independently of one another, a hydrogen atom or a (C 1 -C 6 ) alkyl or aryl group, and
  • heterocycles being optionally substituted by an oxo, (C 1 -C 6 ) alkyl or C0 2 - (C 1 -C 6 ) alkyl group.
  • Rio will preferably represent a group -S (O) 2 Ris.
  • Ris is (Ci-C 6) optionally substituted alkyl, optionally substituted aryl, (Ci-C 6) alkyl-aryl, aryl- (Ci-C 6) alkyl, carbocycle, heterocycle optionally substitute, biaryl, carbocycle- (Ci -C 6 ) alkyl or heterocycle- (C 1 -C 6 ) alkyl.
  • R 26 to R 29 representing, independently of each other, a hydrogen atom or a (C 1 -C 6) alkyl or aryl group.
  • Ris preferably represents a group (Ci-C 6) alkyl optionally substituted with one or more groups (including one) selected from C0 2 R 26, OR 27, and NR 2 SR 2 9, in particular from OR 27 and NR 2 SR 2 ; aryl; (C1-C6) alkyl-aryl; or aryl (C 1 -C 6 ) alkyl.
  • the compounds of the invention may be chosen from the following examples:
  • the subject of the present invention is also a compound according to the invention of formula (I) as defined above, for its use as a medicament, in particular intended for the treatment of cancerous and precancerous hyperproliferative pathologies.
  • the present invention also relates to the use of a compound of formula (I) as defined above, for the manufacture of a medicament, in particular for the treatment of cancerous and pre-cancerous hyperproliferative pathologies.
  • the present invention also relates to a method for treating cancerous and pre-cancerous hyperproliferative pathologies, comprising administering to a person in need of an effective dose of a compound of formula (I) as defined above.
  • cancerous or precancerous hyperproliferative pathologies is intended to mean all types of cancerous or pre-cancerous hyperproliferative pathologies, in particular cancer of the lung, breast, brain and cutaneous cancers.
  • the term "skin cancer” is intended to mean, in particular, actinic keratosis, solar keratosis, keratinocyte intraepithelial neoplasia, cutaneous papillomas, squamous cell carcinomas in situ, squamous cell carcinomas, precancerous skin lesions, basal cell carcinoma including superficial and nodular forms, Bowen's disease, Dubreuilh's melanoma, condylomas, Merkel's tumor, Paget's disease, or mucocutaneous lesions induced by the human papillomavirus.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising at least one compound of formula (I) as defined above, and at least one pharmaceutically acceptable excipient.
  • compositions according to the invention may be formulated especially for oral administration, for topical administration or by injection, said compositions being intended more particularly for mammals, including humans.
  • the active ingredient can be administered in unit dosage forms, in admixture with conventional pharmaceutical carriers, to animals including humans.
  • the compounds of the invention as active ingredients can be used at doses of between 0.01 mg and 1000 mg per day, given as a single dose once a day or administered in several doses throughout the day, for example twice a day in equal doses.
  • the dose administered per day is advantageously between 5 mg and 500 mg, more advantageously between 10 mg and 200 mg. It may be necessary to use doses out of these ranges which the skilled person can realize himself.
  • compositions according to the invention may also comprise at least one other active ingredient, such as an anticancer agent.
  • the present invention also relates to a pharmaceutical composition as defined above for its use as a medicament, in particular for the treatment of cancerous and pre-cancerous hyperproliferative pathologies.
  • the compounds according to the invention have often been obtained in the form of two diastereoisomers which have been separated. However, it was not determined to which of the two NMR spectra obtained corresponded each of these two diastereoisomers.
  • the mixture is heated at 100 ° C. for 16 hours.
  • the reaction mixture is then cooled to room temperature and diluted with water and dichloromethane.
  • the sentence The organic material is washed with saturated NaHCO 3 solution , dried over MgSO 4, filtered and concentrated under reduced pressure.
  • the residue is purified by chromatography on silica gel (eluent dichloromethane / methanol).
  • N1E115 (ATCC, CRL2263), MDA-MB-231 (ATCC, HTB26) and HSC-1 (Health Science Research Resources Bank, JCRB1015) lines were grown in DMEM (Dulbecco's Modified Eagle Medium) supplemented with 2 mM L Glutamine (Sigma, G7513) and 10% fetal calf serum (Hyclone, SH30109.03) or 20% in the case of HSC-1 cells.
  • Lines HCC-1937 (ATCC, CRL2336) and A549 (ATCC, CCL185) were cultured in RPMI medium (Roswell Park Memorial Institute medium) supplemented with 10% fetal calf serum and 2 mM L-Glutamine.
  • the SCO 14 line (DSMZ, ACC662) was cultured in MEM (Essential Essential Medium Eagle) supplemented with 10% fetal calf serum and 2 mM L-Glutamine.
  • MEM Essential Essential Medium Eagle
  • the cells are seeded into their respective culture media with 750 cells per well for N1E115; 1000 cells per well for SCC114 and A549; 2000 cells per well for HCC-1937 and HSC-1; 2500 cells per well for MDA-MB-231.
  • a cascade dilution of each compound was made in dimethylsulfoxide (DMSO) (Sigma, D8418) from stock solutions at 10 mM in 100% DMSO.
  • DMSO dimethylsulfoxide
  • the cytotoxic properties of some compounds of the invention evaluated on lines A549 lung cancer cell line
  • MDA-MB-231 mimmary adenocarcinoma cell line
  • N1E115 neuroroblastoma cell line
  • murine brain HCC-1937
  • HSC-1 cutaneous squamous cell carcinoma cell line
  • SCC114 squamous cell carcinoma cell line
  • the activity of the compounds according to the invention on the HCC line 1997 was compared with that of known cytotoxics (Epotilone B and Vinflunine).
  • the compounds according to the invention exhibit a particularly remarkable activity on this particularly resistant breast cancer cell line.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP13744551.6A 2012-08-01 2013-08-01 Griseofulvinderivate Withdrawn EP2880024A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1257482 2012-08-01
PCT/EP2013/066169 WO2014020105A1 (fr) 2012-08-01 2013-08-01 Derives de griseofulvine

Publications (1)

Publication Number Publication Date
EP2880024A1 true EP2880024A1 (de) 2015-06-10

Family

ID=47178080

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13744551.6A Withdrawn EP2880024A1 (de) 2012-08-01 2013-08-01 Griseofulvinderivate
EP13744549.0A Withdrawn EP2880023A1 (de) 2012-08-01 2013-08-01 Griseofulvinderivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP13744549.0A Withdrawn EP2880023A1 (de) 2012-08-01 2013-08-01 Griseofulvinderivate

Country Status (3)

Country Link
US (3) US9416143B2 (de)
EP (2) EP2880024A1 (de)
WO (2) WO2014020105A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014020105A1 (fr) * 2012-08-01 2014-02-06 Pierre Fabre Medicament Derives de griseofulvine
HUE058182T2 (hu) 2016-03-30 2022-07-28 Daiichi Sankyo Co Ltd Grizeofulvin vegyület
TWI811243B (zh) 2017-09-29 2023-08-11 日商第一三共股份有限公司 灰黃黴素化合物及醫藥用途
EP4125865A4 (de) * 2020-04-02 2024-05-08 Sirtsei Pharmaceuticals, Inc. Zusammensetzungen und verfahren zum behandeln von altersbedingten krankheiten und vorzeitigen alterungsstörungen
CN112979665B (zh) * 2021-02-07 2021-11-19 南通大学 一种灰黄霉素施密特重排衍生物及其制备方法
CN113861144B (zh) * 2021-08-04 2022-06-21 南通大学 一种灰黄霉素开环衍生物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2008652A1 (de) * 2007-06-28 2008-12-31 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Griseofulvinanaloge zur Behandlung von Krebs durch Hemmung von zentrosomalem Clustering
EP2204367A1 (de) * 2008-12-22 2010-07-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Griseofulvinanaloge zur Behandlung von Krebs durch Hemmung von zentrosomalem Clustering
WO2014020105A1 (fr) * 2012-08-01 2014-02-06 Pierre Fabre Medicament Derives de griseofulvine

Also Published As

Publication number Publication date
US20160289204A1 (en) 2016-10-06
US20150210713A1 (en) 2015-07-30
US20150191443A1 (en) 2015-07-09
EP2880023A1 (de) 2015-06-10
US9416142B2 (en) 2016-08-16
WO2014020105A1 (fr) 2014-02-06
US9416143B2 (en) 2016-08-16
WO2014020101A1 (fr) 2014-02-06

Similar Documents

Publication Publication Date Title
KR100991920B1 (ko) 사이클린-의존성 키나제의 억제제 및 그 용도
WO2014020105A1 (fr) Derives de griseofulvine
EP3164393B1 (de) Flavagline derivate
JPS58131978A (ja) アスコルビン酸エ−テルおよび関連化合物
CN114149423B (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
JPH09512831A (ja) ジベンズイミダゾール誘導体
CN110156674A (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
KR20190135038A (ko) 구아니딘 유도체
AU2019221837B2 (en) Agents and methods for treating dysproliferative diseases
FR2801310A1 (fr) NOUVEAUX DERIVES DE DIHYDROFURO-[3,4-b]QUINOLEIN-1-ONES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
JPS61501854A (ja) 新規なド−パミン・アゴニスト
CN110305123B (zh) 一种含有金刚烷的化合物及其在治疗癌症中的用途
JPS63152374A (ja) ヒドロキシブテノライド誘導体およびその製造法
JP3795093B2 (ja) １−ヒドロキシインドール誘導体
EP1664055A1 (de) 9-aminopodophyllotoxinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese derivate enthalten
US9381260B2 (en) Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents
WO2004000834A1 (fr) Nouveaux derives de 3-(4-oxo-4h-chromen-2-yl)-(1h)-quinolein-4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPH0699364B2 (ja) ズルシート類、その製造方法および該化合物の製造方法
CN113387807B (zh) Akendo 3二萜衍生物及其制备和用途
EP1474390B1 (de) Indolderivate substituiert mit langkettigen alcoholen und sie enthaltende arzneimittel
JP5476650B2 (ja) 新規ｄｉｆ−１誘導体
EP0982308B1 (de) 8H-(2,3-b)-Pyrrolozin-8-one Derivate, Verfahren zur ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
FR2814166A1 (fr) Derives 5-phenoxyindole et leurs applications therapeutiques
MC1264A1 (fr) Procede de preparation de benzylpyrimides et de medicaments contenant ces substances
EP3189061A1 (de) Derivate von makrocyclischen n-aryl-tricyclopyrimidin-2-amin-polyethern als inhibitoren von ftl3 und jak

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150226

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170201

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170613